Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study

BackgroundThe 5-year event-free survival rate for childhood acute lymphoblastic leukemia (ALL) has increased to more than 85%. However, the 5-year overall survival rate in children with relapsed/refractory ALL did not exceed 50%. In the past decade, immunotherapies (such as blinatumomab and chimeric...

Full description

Bibliographic Details

Published in:	Frontiers in Pediatrics
Main Authors:	Songmi Wang, Aiguo Liu, Na Wang, Yaqin Wang, Ai Zhang, Li Wang, Wen Yu, Chunrui Li, Yicheng Zhang, Qun Hu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Subjects:	acute leukemia pediatric immunotherapy blinatumomab chimeric antigen receptor T cells
Online Access:	https://www.frontiersin.org/articles/10.3389/fped.2022.1100404/full